1835 / 1851
Toxicity of concurrent SRT and
BRAF-inhibitors
vemurafenib, dabrafenib
Conflicting data on CNS toxicity after cranial SRT and
BRAF-inhibitors
High rates of toxicity warrant caution.
No data on BRAF inhibitors and extra-cranial SRT.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37